Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
AY.23.2 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.104 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.198NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EG.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XAFNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BC.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
P.1.17.1 (Gamma)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.3.16NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.41NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.375NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BL.1.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.75.9NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBHNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BL.1.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BQ.1.1.78NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.9.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BQ.1.1.64NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBC.1.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.221.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
DP.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BL.1.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BN.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.62NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.82NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.20NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.3.22NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.38.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GS.8NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GE.1.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.5.93NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.2.3.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.4.8NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EG.5.1.18NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HK.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GM.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.13.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GV.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EG.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HH.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EM.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FD.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GF.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EG.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.5.24NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FU.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.4.6NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GY.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.16.18NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used